Abstract:KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer. On the other hand, pancreatic cancer harbors other KRAS mutations such as G12D and G12V. The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking. Unfortunately, KRAS inhibitor monotherapy-associated resistance hinders their therapeutic efficacy. Therefore, various combination strategies have been tested and some yielded promising results, such as combinations with receptor tyrosine kinase, SHP2, or SOS1 inhibitors. In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-XL-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo. This is in part because KRAS-targeted therapies induce cell cycle arrest and cellular senescence, which contributes to therapeutic resistance, while their combination with DT2216 can more effectively induce apoptosis. Similar combination strategies may also work for G12D inhibitors in pancreatic cancer. This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.

Targeting KRAS in gynecological malignancies

Clinical and genomic landscape of RAS mutations in gynecologic cancers

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting KRAS in Colorectal Cancer

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Targeting KRAS G12C Mutations in Colorectal Cancer.

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Targeting KRAS in cancer

Advances in KRAS mutation inhibition in metastatic colorectal cancer

KRAS mutation: from undruggable to druggable in cancer

Targeting KRAS in Non-Small Cell Lung Cancer

Targeting KRASG12D Mutation in Non-Small Cell Lung Cancer: Molecular Mechanisms and Therapeutic Potential

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Metastatic gynecologic malignancies: advances in treatment and management

Emerging strategies to target RAS signaling in human cancer therapy

Mutational Analysis Ofkrasand Its Clinical Implications in Cervical Cancer Patients

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer